Drug Trial Radar · NCT06952803
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
700
Planned (sponsor's estimate)
Start
Aug 6, 2025
Primary completion
Mar 31, 2033
Study completion Apr 30, 2036
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- May 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in participants with high-risk and very high-risk localised/locally advanced prostate cancer with a breast cancer gene mutation (BRCAm).
Conditions
- Prostate Cancer
Interventions
SaruparibDrug
Saruparib will be administered orally.
PlaceboDrug
Matching placebo to saruparib will be administered orally.
Abiraterone + Prednisolone/PrednisoneDrug
Abiraterone will be administered orally in combination with prednisone/prednisolone.
Androgen Deprivation Therapy (ADT)Drug
Standard of care ADT will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Metastasis-free survival (MFS)Time frame: Up to approximately 93 months
Locations
346 sites in 28 countries. Site status is shown where the registry gives one.
Research Site
Phoenix, Arizona · Recruiting
Research Site
Tucson, Arizona · Withdrawn
Research Site
La Jolla, California · Recruiting
Research Site
La Jolla, California · Recruiting
Research Site
Los Angeles, California · Recruiting
Research Site
San Diego, California · Recruiting
Research Site
San Luis Obispo, California · Recruiting
Research Site
Lakewood, Colorado · Recruiting
Research Site
Hialeah, Florida · Recruiting
Research Site
Jacksonville, Florida · Recruiting
Research Site
Tallahassee, Florida · Withdrawn
Research Site
Tampa, Florida · Recruiting
Research Site
Newnan, Georgia · Recruiting
Research Site
Chicago, Illinois · Recruiting
Research Site
Chicago Ridge, Illinois · Recruiting
Research Site
Lake Barrington, Illinois · Withdrawn
Research Site
Greenwood, Indiana · Recruiting
Research Site
Jeffersonville, Indiana · Withdrawn
Research Site
Bethesda, Maryland · Withdrawn
Research Site
Towson, Maryland · Recruiting
Research Site
Plymouth, Massachusetts · Recruiting
Research Site
Rochester, Minnesota · Recruiting
Research Site
Hackensack, New Jersey · Recruiting
Research Site
Voorhees Township, New Jersey · Recruiting
Research Site
Albany, New York · Withdrawn
Research Site
New York, New York · Recruiting
Research Site
Syracuse, New York · Recruiting
Research Site
Columbus, Ohio · Recruiting
Research Site
Springfield, Oregon · Recruiting
Research Site
Hershey, Pennsylvania · Recruiting
Research Site
Lancaster, Pennsylvania · Recruiting
Research Site
Pittsburgh, Pennsylvania · Recruiting
Research Site
Providence, Rhode Island · Recruiting
Research Site
Myrtle Beach, South Carolina · Recruiting
Research Site
Nashville, Tennessee · Recruiting
Research Site
Austin, Texas · Recruiting
Research Site
Austin, Texas · Recruiting
Research Site
Houston, Texas · Recruiting
Research Site
San Antonio, Texas · Recruiting
Research Site
Spring, Texas · Recruiting
Showing 40 of 346 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.